Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Auxier Asset Management

Auxier Asset Management lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,573 shares of the medical equipment provider’s stock after buying an additional 2,070 shares during the quarter. Auxier Asset Management’s holdings in Zimmer Biomet were worth $6,863,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in ZBH. BLB&B Advisors LLC increased its holdings in shares of Zimmer Biomet by 2.1% in the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after acquiring an additional 100 shares during the period. FWG Holdings LLC increased its stake in shares of Zimmer Biomet by 2.9% in the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock valued at $372,000 after purchasing an additional 101 shares during the period. Financial Advocates Investment Management raised its holdings in shares of Zimmer Biomet by 3.5% during the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after buying an additional 103 shares during the last quarter. M&R Capital Management Inc. boosted its position in shares of Zimmer Biomet by 14.1% during the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 105 shares during the period. Finally, Mill Creek Capital Advisors LLC grew its holdings in Zimmer Biomet by 5.1% in the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock worth $238,000 after buying an additional 106 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on ZBH. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. TD Cowen decreased their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. BTIG Research lowered their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Wells Fargo & Company increased their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, Oppenheimer cut their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $123.22.

Zimmer Biomet Trading Up 1.2 %

Shares of Zimmer Biomet stock opened at $112.02 on Friday. The firm’s 50-day moving average price is $107.18 and its two-hundred day moving average price is $109.50. The company has a market capitalization of $22.30 billion, a price-to-earnings ratio of 21.30, a PEG ratio of 2.06 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.65 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.